Labopharm to be acquired by Paladin Labs

Labopharm (NASDAQ:DDSS; TSX:DDS) has accepted a takeover bid from Paladin Labs (TSX:PLB), which will make an offer for all of the common shares of Labopharm at a price of 28.57 cents a share in cash. The purchase price represents a premium of 57.4% over the volume-weighted average price of Labopharm’s shares of 18.15 cents for the 30 trading [...]

Labopharm partner loses tramadol patent appeal

The U.S. Court of Appeals for the Federal Circuit has ruled that Purdue Pharma Products’ patent claims for controlled-release tramadol, a pain medication, are invalid.  Purdue distributes Labopharm’s (TSX:DDS; NASDAQ:DDSS) tramadol drug Ryzolt in the U.S. Generic drug maker Par Pharmaceutical (NYSE:PRX) had argued that the patent claims should be deemed invalid because they were [...]

Analysts cut Labopharm price targets on marketing deal

After weighing the pros and cons of Labopharm’s joint venture marketing accord with Italy’s Gruppo Angelini, Dundee Securities and Versant Partners cut their price targets on “buy-rated” Labopharm (TSX: DDS; NASDAQ: DDSS), with Dundee moving the target down to $2.40 from $3 and Versant down to $2.50 from $3. Dundee analyst David Martin cited “increased [...]

Yorkville in financing pact with Allon

YA Global Master SPV, a fund managed by Yorkville Advisors LLC, has made its third standby equity distribution agreement in the Canadian biotech sector in recent months, agreeing to provide up to $10 million of capital to Allon Therapeutics (TSX:NPC) over the next three years at Allon’s discretion. “We are enthusiastic about our investment in [...]

Labopharm closes public offering of units

Labopharm (TSX:DDS; NASDAQ:DDSS) has closed a public offering of 11,764,706 units priced at $1.70 (U.S.) a unit for net proceeds of $18.15 million, after deducting underwriting and estimated offering expenses. Each unit consists of one common share and a warrant to purchase 0.5 of a common share.  Each warrant entitles the holder to acquire one [...]

Labopharm’s new antidepressant to be ‘game-changer’

It’s game on for Labopharm (TSX:DDS; NASDAQ:DDSS). By February 11, the FDA is expected to approve the company’s antidepressant trazodone, a novel once-daily formulation that addresses many of the shortcomings of similar drugs on the market.  “I think it’s fair to say this drug could be a game-changer for us,” CEO James Howard-Tripp says in [...]

Dundee biotech outlook sees ‘ample room for upside’

While we were at the J.P. Morgan Healthcare Conference in San Francisco last week, Dundee Securities issued its latest biotech sector update. On the bright side, analyst David Martin writes that there are signs Biovail, Angiotech and QLT stocks are bouncing back – supported by new strategies and new products in development for each company. [...]

Labopharm inks U.K. distribution pact

Labopharm has signed an agreement with Merck Sharp & Dohme (MSD) of Britain for the distribution and marketing of Labopharm’s once-daily tramadol pain drug, Tradorec XL in England, Northern Ireland, Scotland, Wales, the Channel Islands and the Isle of Man. Under the accord with the British unit of Merck (NYSE:MRK), Labopharm will supply MSD with [...]

Labopharm files tramadol-acetaminophen drug in Europe

Labopharm (TSX:DDS) has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under a decentralized procedure (DCP) system. “Initiating the regulatory approval process in Europe builds on our recently established marketing partnership with Grenenthal GmbH,” Labopharm CEO James Howard-Tripp said in a statement. “It is our intention to commercialize our twice-daily tramadol-acetaminophen [...]

Labopharm’s trazodone drug in peer-reviewed medical journal

An article in the October issue of CNS Spectrums, an international journal of neuropsychiatric medicine, cites the potential benefits of Labopharm’s new trazodone formulation, which contains its Contramid technology to control the release of active ingredients to improve drug delivery. “Although trazodone has traditionally been used as a low dose hypnotic, a new controlled release [...]

Next Page »